Your fast, high-signal look at everything that moved biotech, medtech, and pharma today. The BioMed Nexus Daily Update delivers the most important regulatory moves, trial readouts, deals, and industry developments in one concise, easy-to-scan report. Updated every weekday morning.
This was the best quarter in Lilly’s history by virtually every metric. Revenue of $19.8 billion, up 56% year-over-year, smashed the Street consensus of $17.6
Earnings season is separating the winners from the wounded. AstraZeneca beat across the board, passed $15 billion in quarterly sales, and reaffirmed its $80 billion
Lilly is buying a company a week. That is not hyperbole. Since February, Lilly has announced five acquisitions totaling approximately $19.8 billion in committed capital:
India’s largest drugmaker just made the biggest outbound pharma acquisition in the country’s history. Sun Pharmaceutical Industries announced a definitive agreement to acquire Organon for
This is one of the most important Foundayo data points since the drug was approved. The Phase 3 ACHIEVE-4 trial enrolled more than 2,700 patients
The BALANCE setback is the most significant GLP-1 policy development since the Section 232 tariff announcement. CMS shelved its five-year Medicare Part D demonstration for
Revolution Medicines was “the talk of the town” at AACR this week, as STAT put it, and yesterday’s data explained why. The combination of daraxonrasib
Lilly is building an oncology franchise with the same speed and conviction it used to dominate GLP-1s. The Kelonia Therapeutics deal—up to $7 billion ($3.25
Kailera Therapeutics just told you everything you need to know about the obesity market in April 2026. An 18-month-old company built around Chinese-licensed GLP-1 assets
Two days. That is how long it took Revolution Medicines to turn landmark Phase 3 pancreatic cancer data into the largest follow-on stock offering in
